Associate Clinical Professor of Medicine, UCLA-David Geffen School of Medicine
Oncology
Dr. Merry L. Tetef, MD
|
|
Give Review
Doctor Merry L. Tetef, MD is an expert in the field of Oncology. She studied medicine at Harvard Medical School. Harvard Medical School is a top medical university. Harvard Medical School has a rank of 1 in research and a 12 in primary care She received 5 awards: "Top Doctors:LA Area", "Top Doctors:San Diego Area", "Top Doctors:Southern California", "Super Doctor" and "Top MD". Doctor Merry L. Tetef, MD is a published doctor and has 27 publications published. The lastest was: 'High-dose infusional doxorubicin and cyclophosphamide: a feasibility study of tandem high-dose chemotherapy cycles without stem cell support.' Doctor Merry L. Tetef, MD accepts all Medicare patients.
Publications
- Phase II studies of gemcitabine and cisplatin in heavily and minimally pretreated metastatic breast Cancer.
- Phase I trial of intraperitoneal iododeoxyuridine with and without intravenous high-dose folinic acid in the treatment of advanced malignancies primarily confined to t...
- High-dose chemotherapy and stem-cell rescue in the treatment of high-risk breast Cancer: prognostic indicators of progression-free and overall survival.
- Effect of CD34+ selection and various schedules of stem Cell reinfusion and granulocyte colony-stimulating factor priming on hematopoietic recovery after high-dose che...
- Pharmacokinetics and toxicity of 120-hour continuous-infusion hydroxyurea in patients with advanced solid Tumors.
- Treatment of germ cell Cancer with two cycles of high-dose ifosfamide, carboplatin, and etoposide with autologous stem-cell support.
- Mitomycin C and menadione for the treatment of lung Cancer: a phase II trial.
- Mitomycin C and menadione for the treatment of advanced gastrointestinal Cancers: a phase II trial.
- 5-Fluorouracil and high-dose calcium leucovorin for hepatoCellular carcinoma: a phase II trial.
- Recombinant human thrombopoietin in combination with granulocyte colony-stimulating factor enhances mobilization of peripheral blood progenitor Cells, increases periph...
- Cisplatin and infusional cytosine arabinoside for the treatment of coloRectal adenocarcinoma: a phase II trial.
- High-dose infusional doxorubicin and cyclophosphamide: a feasibility study of tandem high-dose chemotherapy cycles without stem Cell support.
- Keratin immunohistochemistry detects clinically significant metastases in bone marrow biopsy specimens in women with lobular breast Carcinoma.
- Tandem-cycle high-dose melphalan and cisplatin with peripheral blood progenitor cell support in patients with breast Cancer and other malignancies.
- Continuous infusion prochlorperazine: pharmacokinetics, antiemetic efficacy, and feasibility of high-dose therapy.
- Phase II trial of carboplatin and infusional cyclosporine with alpha-interferon in recurrent ovarian Cancer: a California Cancer Consortium Trial.
- Phase I trial of intraperitoneal gemcitabine in the treatment of advanced malignancies primarily confined to the peritoneal cavity.
- Phase I study of cisdiamminedichloroplatinum in combination with azidothymidine in the treatment of patients with advanced malignancies.
- Phase II trial of carboplatin and infusional cyclosporine in platinum-resistant recurrent ovarian Cancer.
- Feasibility and pharmacokinetic study of infusional dexrazoxane and dose-intensive doxorubicin administered concurrently over 96 h for the treatment of advanced malign...
- A phase I study of carboplatin and etoposide administered in conjunction with dipyridamole, prochlorperazine and cyclosporine A.
- Pharmacokinetics and toxicity of high-dose intravenous methotrexate in the treatment of leptomeningeal Carcinomatosis.
- Antineoplastic activity of continuous exposure to dexrazoxane: potential new role as a novel topoisomerase II inhibitor.
- Phase I trial of 96-hour continuous infusion of dexrazoxane in patients with advanced malignancies.
- High-dose paclitaxel in combination with doxorubicin, cyclophosphamide and peripheral blood progenitor Cell rescue in patients with high-risk primary and responding me...
- A study of radiotherapy modalities combined with continuous 5-FU infusion for locally advanced gastrointestinal malignancies.
Schools
Harvard Medical School
Procedures Preformed
- Thoracentesis
Conditions Treated
- Adrenal Gland Cancer
- Anal and Rectal Cancer
- Anemia
- Basal Cell Carcinoma
- View All
Doctors Specialties
- Medical Oncology
- Oncology
Accepted Insurances
Awards
- Top Doctors:LA Area
- Top Doctors:San Diego Area
- Top Doctors:Southern California
- Super Doctor
- Top MD
Education
-
UCLA Medical Center -
Harvard Medical School
Hospital
-
Ronald Reagan UCLA Medical Center -
Hoag Memorial Hospital Presbyterian -
St. Joseph Hospital
Drug Facts
| NPI NUMBER | 1194784785 | |
| NPPES Provider LastName | TETEF | |
| NPPES Provider FirstName | MERRY | |
| NPPES Provider ZIPCode | 926044728 | |
| NPPES Provider State | CA | |
| Specialty Description | Hematology/Oncology | |
| Total Claim Count | 909.0 | |
| Distinct Opioid Count | 2.0 | |
| Opioid Claim Count | 36.0 | |
| Percent Opioid Claims | 3.96 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1194784785 |
| Last Name Of The Provider | TETEF |
| First Name Of The Provider | MERRY |
| View All |
Similar Doctors
|
|
Dr. Shlomit Y. Ein-Gal, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Louis A. Vandermolen Jr., MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Paul H. Coluzzi, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Merry L. Tefef, MD |
|
|
Dr. Sarah E. Stanton, MD
This Doctor is OpenDoctor Recommended.
|